Overview
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist marketed by Eli Lilly under the brand name Trulicity. Approved by the FDA in September 2014 for type 2 diabetes, dulaglutide consists of two GLP-1 analog molecules covalently linked to a modified human IgG4 Fc fragment, which extends its half-life and supports once-weekly subcutaneous dosing. The REWIND cardiovascular outcomes trial in 9,901 patients with type 2 diabetes demonstrated a 12% relative risk reduction in major adverse cardiovascular events over a median 5.4 years, making dulaglutide one of only a few GLP-1 agents with confirmed primary-prevention cardiovascular benefit. Dulaglutide is widely used as a comparator in head-to-head trials of newer agents such as tirzepatide.
Mechanism of Action
Dulaglutide activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release from alpha cells, slowing gastric emptying, and acting on hypothalamic centers to reduce appetite. The Fc fusion protects the peptide from DPP-4 degradation and confers a half-life of approximately 4.5 to 4.7 days, supporting steady-state plasma exposure within 2 to 4 weeks of weekly dosing. Cardiovascular benefit is thought to involve direct vascular GLP-1 receptor effects, anti-inflammatory action on macrophages, modest blood pressure reduction, and weight-mediated improvements in glycemia.
Potential Benefits
- FDA-approved for type 2 diabetes (Trulicity, 2014) and reduction of major adverse cardiovascular events in adults with T2D and established CV disease or multiple CV risk factors
- REWIND trial: 12% relative risk reduction in MACE over 5.4 years (HR 0.88, 95% CI 0.79-0.99)
- HbA1c reduction of approximately 1.0 to 1.5 percent across pivotal AWARD trials
- Modest weight loss (typically 2 to 3 kg)
- Once-weekly subcutaneous dosing via prefilled pen
- Established safety and efficacy profile from over a decade of post-marketing use
Research Dosage Notes
The following reflects doses used in published research studies. This is not medical advice.
Starting dose 0.75 mg subcutaneously once weekly. May increase to 1.5 mg weekly for additional glycemic control. Doses of 3 mg and 4.5 mg weekly are also available for further A1C reduction. Half-life approximately 4.7 days.
Amino Acid Sequence
Two GLP-1 analog peptides (A8G, G22E, R36G modifications) linked via small peptide spacer to human IgG4 Fc fragment
Side Effects & Safety
- Nausea, diarrhea, vomiting (dose-related, typically transient)
- Decreased appetite
- Injection site reactions
- Increased risk of acute pancreatitis (rare)
- Boxed warning for thyroid C-cell tumors based on rodent studies
- Gallbladder disease risk
Synergistic Compounds
The following compounds have been studied alongside Dulaglutide for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
Enicepatide (CT-388): Roche's biased GLP-1/GIP peptide drops Phase 2 detail at ADA 2026
Roche's enicepatide (CT-388) hit 22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 with no plateau; Phase 3 enrolling.
Canvuparatide one-year data: once-weekly PTH peptide prodrug stays on track for Phase 3
MBX Biosciences reported one-year open-label data for once-weekly canvuparatide in chronic hypoparathyroidism. Phase 3 starts Q3 2026.
State pharmacy boards escalate peptide enforcement: what April–May 2026 actions signal
April–May 2026 actions in TX, FL, CA, and OH show state boards targeting peptide and compounded GLP-1 practices via records, prescriber relationships, and volume.
Peptide Import Inspections Are the New Front Line for Compounding Enforcement (Q1 2026)
New Q1 2026 import data suggests selective border enforcement for unapproved peptides and helps explain why compounding policy is shifting this summer.